India, April 27 -- Jagsonpal Pharmaceuticals Limited has received shareholder approval for its proposed share buyback, reinforcing its focus on enhancing shareholder value.
The company had earlier announced a buyback of up to 16 lakh equity shares at Rs 250 per share, aggregating to a total value of up to Rs 40 crore. The approval reflects strong investor confidence in the company's strategic direction and financial discipline.
The buyback aims to optimize capital allocation, improve earnings per share (EPS), and deliver better returns to shareholders, while maintaining a balance between growth investments and capital returns.
Further details regarding timelines and the record date for the buyback will be announced in due course, in line...